Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.

Jon T GilesNaveed SattarSherine GabrielPaul M RidkerSteffen GayCharles WarneDavid MusselmanLaura BrockwellEmma ShittuMicki KlearmanThomas R Fleming

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)

The results of this trial, which provide insights into the CV safety of tocilizumab as compared to etanercept, ruled out a risk for occurrence of MACE of 1.43 or higher in patients treated with tocilizumab. This result should be interpreted in the context of the clinical efficacy and non-CV safety of tocilizumab.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
rheumatoid arthritis patients
disease activity
ankylosing spondylitis
interstitial lung disease
risk assessment
clinical trial
study protocol
randomized controlled trial
systemic sclerosis
double blind